Allarity Therapeutics A/S

Headquarters: Horsholm, Denmark

Employees: 14

CEO: Mr. Stefano R. Carchedi

OMX: ALLR -26.54%

Market Cap

kr932.6 Million

SEK as of Dec. 1, 2021

US$103.1 Million

history Market Cap History

Allarity Therapeutics A/S market capitalization over time

Evolution of Allarity Therapeutics A/S market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Allarity Therapeutics A/S

Detailed Description

Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.


"Bulls make money...
Bears make money...
Pigs get slaughtered!"

Stop guessing, unlock Financial AI.

(Don't be a pig.)

Stocks & Indices

Allarity Therapeutics A/S has the following listings and related stock indices.

Stock: OMX: ALLR wb_incandescent



Venlighedsvej 1

Horsholm, 2970


Phone: 45 88 74 24 14